Drug disposition alterations in liver disease: Extrahepatic effects in cholestasis and nonalcoholic steatohepatitis

Expert Opinion on Drug Metabolism and Toxicology

Volumn 10, Issue 9, 2014, Pages 1209-1219

  Canet, Mark J ^a   Cherrington, Nathan J ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Adverse drug reactions; Cytochrome P450; Liver disease; Membrane transporters; Pharmacokinetics

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450; EFAVIRENZ; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHOTREXATE; PRAVASTATIN; TRAMADOL; XENOBIOTIC AGENT; CARRIER PROTEIN; DRUG;

ADVERSE OUTCOME; AREA UNDER THE CURVE; CARDIOVASCULAR DISEASE; CHOLESTASIS; DRUG DISPOSITION; DRUG EXCRETION; DRUG METABOLISM; GENETIC POLYMORPHISM; GENETICS; HUMAN; MYOPATHY; NONALCOHOLIC FATTY LIVER; NONHUMAN; REVIEW; XENOBIOTIC METABOLISM; ANIMAL; METABOLISM; PATHOPHYSIOLOGY; PHARMACOKINETICS;

ANIMALS; CHOLESTASIS; HUMANS; MEMBRANE TRANSPORT PROTEINS; NON-ALCOHOLIC FATTY LIVER DISEASE; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; XENOBIOTICS;

EID: 84906053661     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2014.936378     Document Type: Review

References (91)

1. Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Ann Intern Med 2004;140(10):795-801
2. Bond CA, Raehl CL. Adverse drug reactions in United States hospitals. Pharmacotherapy 2006;26(5):601-8
3. Howard RL, Avery AJ, Slavenburg S, et al. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol 2007;63(2):136-47
4. Wooten JM. Adverse drug reactions: part I. South Med J 2010;103(10):1025-8
5. Sultana J, Cutroneo P, Trifiro G. Clinical and economic burden of adverse drug reactions. J Pharmacol Pharmacother 2013;4(Suppl1):S73-7
6. Valente S, Murray LP. Creative strategies to improve patient safety: allergies and adverse drug reactions. J Nurses Staff Dev 2011;27(1):E1-5
7. Shepherd G, Mohorn P, Yacoub K, May DW. Adverse drug reaction deaths reported in United States vital statistics, 1999-2006. Ann Pharmacother 2012;46(2):169-75
8. Baye TM, Abebe T, Wilke RA. Genotype-environment interactions and their translational implications. Per Med 2011;8(1):59-70
9. Hodgson J. ADMET-turning chemicals into drugs. Nat Biotechnol 2001;19(8):722-6
10. Fan J, de Lannoy IAM. Pharmacokinetics. Biochem Pharmacol 2014;87(1):93-120
11. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013;138(1):103-41
12. Zhang Y, Klein K, Sugathan A, et al. Transcriptional profiling of human liver identifies sex-biased genes associated with polygenic dyslipidemia and coronary artery disease. PLoS One 2011;6(8):e23506
13. Wolbold R, Klein K, Burk O, et al. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 2003;38(4):978-88
14. Koukouritaki SB, Manro JR, Marsh SA, et al. Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther 2004;308(3):965-74
15. Stevens JC, Marsh SA, Zaya MJ, et al. Developmental changes in human liver CYP2D6 expression. Drug Metab Dispos 2008;36(8):1587-93
16. Sim SC, Kacevska M, Ingelman-Sundberg M. Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects. Pharmacogenomics J 2013;13(1):1-11
17. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19*2 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009;373(9660):309-17
18. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360(4):363-75
19. Sofi F, Giusti B, Marcucci R, et al. Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J 2011;11(3):199-206
20. Jang JS, Cho KI, Jin HY, et al. Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel. Am J Cardiol 2012;110(4):502-8
21. Bauer T, Bouman HJ, van Werkum JW, et al. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ 2011;343:d4588
22. Holmes MV, Perel P, Shah T, et al. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 2011;306(24):2704-14
23. Manosuthi W, Sukasem C, Thongyen S, et al. CYP2B6 18492T->C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1. Antimicrob Agents Chemother 2014;58(4):2268-73
24. Sukasem C, Manosuthi W, Koomdee N, et al. Low level of efavirenz in HIV-1-infected Thai adults is associated with the CYP2B6 polymorphism. Infection 2014;42(3):469-74
25. Xu J, Zhang XC, Lv XQ, et al. Effect of the cytochrome P450 2D6*10 genotype on the pharmacokinetics of tramadol in post-operative patients. Pharmazie 2014;69(2):138-41
26. Prieto-Perez R, Ochoa D, Cabaleiro T, et al. Evaluation of the relationship between polymorphisms in CYP2C8 and CYP2C9 and the pharmacokinetics of celecoxib. J Clin Pharmacol 2013;53(12):1261-7
27. Keogh JP. Membrane transporters in drug development. Adv Pharmacol 2012;63:1-42
28. Klaassen CD, Aleksunes LM. Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev 2010;62(1):1-96
29. Liu Y, Yin Y, Sheng Q, et al. Association of ABCC2-24C>T polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemia. PLoS One 2014;9(1):e82681
30. Sparreboom A, Gelderblom H, Marsh S, et al. Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin Pharmacol Ther 2004;76(1):38-44
31. Dessilly G, Elens L, Panin N, et al. ABCB1 1199G>A genetic polymorphism (Rs2229109) influences the intracellular accumulation of tacrolimus in HEK293 and K562 recombinant cell lines. PLoS One 2014;9(3):e91555
32. Gong IY, Kim RB. Impact of genetic variation in OATP transporters to drug disposition and response. Drug Metab Pharmacokinet 2013;28(1):4-18
33. Eley T, He B, Chang I, et al. The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor. Antivir Ther 2014. [Epub ahead of print]
34. Gupta SK, Kantesaria B, Glue P. Pharmacokinetics and safety of singledose ribavirin in patients with chronic renal impairment. Drug Discov Ther 2013;7(4):158-63
35. Weil A, Martin P, Smith R, et al. Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment. Clin Pharmacokinet 2010;49(9):607-18
36. Tortorici MA, Toh M, Rahavendran SV, et al. Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics. Invest New Drugs 2011;29(6):1370-80
37. Weiner IM, Roth L. Renal excretion of cimetidine. J Pharmacol Exp Ther 1981;216(3):516-20
38. Salen G, Nicolau G, Shefer S, Mosbach EH. Hepatic cholesterol metabolism in patients with gallstones. Gastroenterology 1975;69(3):676-84
39. Chai J, He Y, Cai SY, et al. Elevated hepatic multidrug resistance-associated protein 3/ATP-binding cassette subfamily C 3 expression in human obstructive cholestasis is mediated through tumor necrosis factor alpha and c-Jun NH2-terminal kinase/stress-activated protein kinase-signaling pathway. Hepatology 2012;55(5):1485-94
40. Gartung C, Ananthanarayanan M, Rahman MA, et al. Down-regulation of expression and function of the rat liver Na+/bile acid cotransporter in extrahepatic cholestasis. Gastroenterology 1996;110(1):199-209
41. Zollner G, Fickert P, Zenz R, et al. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology 2001;33(3):633-46
42. Slitt AL, Allen K, Morrone J, et al. Regulation of transporter expression in mouse liver, kidney, and intestine during extrahepatic cholestasis. Biochim Biophys Acta 2007;1768(3):637-47
43. Dumont M, Jacquemin E, D'Hont C, et al. Expression of the liver Na+-independent organic anion transporting polypeptide (OATP-1) in rats with bile duct ligation. J Hepatol 1997;27(6):1051-6
44. Brcakova E, Fuksa L, Cermanova J, et al. Alteration of methotrexate biliary and renal elimination during extrahepatic and intrahepatic cholestasis in rats. Biol Pharm Bull 2009;32(12):1978-85
45. Hasegawa Y, Kishimoto S, Takahashi H, et al. Altered expression of MRP2, MRP3 and UGT2B1 in the liver affects the disposition of morphine and its glucuronide conjugate in a rat model of cholestasis. J Pharm Pharmacol 2009;61(9):1205-10
46. Frances B, Gout R, Campistron G, et al. Morphine-6-glucuronide is more muselective and potent in analgesic tests than morphine. Prog Clin Biol Res 1990;328:477-80
47. Jin HE, Hong SS, Choi MK, et al. Reduced antidiabetic effect of metformin and down-regulation of hepatic Oct1 in rats with ethynylestradiol-induced cholestasis. Pharm Res 2009;26(3):549-59
48. Gujral JS, Farhood A, Bajt ML, Jaeschke H. Neutrophils aggravate acute liver injury during obstructive cholestasis in bile duct-ligated mice. Hepatology 2003;38(2):355-63
49. Allen K, Jaeschke H, Copple BL. Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis. Am J Pathol 2011;178(1):175-86
50. Bohan A, Chen WS, Denson LA, et al. Tumor necrosis factor alpha-dependent up-regulation of Lrh-1 and MRP3 (ABCC3) reduces liver injury in obstructive cholestasis. J Biol Chem 2003;278(38):36688-98
51. Bemelmans MH, Gouma DJ, Greve JW, Buurman WA. Cytokines tumor necrosis factor and interleukin-6 in experimental biliary obstruction in mice. Hepatology 1992;15(6):1132-6
52. Okada K, Shoda J, Taquchi K, et al. Nrf2 counteracts cholestatic liver injury via stimulation of hepatic defense systems. Biochem Biophys Res Commun 2009;389(3):431-6
53. Tanaka Y, Aleksunes LM, Cui YJ, Klaassen CD. ANIT-induced intrahepatic cholestasis alters hepatobiliary transporter expression via Nrf2-dependent and independent signaling. Toxicol Sci 2009;108(2):247-57
54. Chen P, Zeng H, Wang Y, et al. Low dose of oleanolic acid protects against lithocholic acid-induced cholestasis in mice: potential involvement of nuclear factor-E2-related factor 2-mediated upregulation of multidrug resistanceassociated proteins. Drug Metab Dispos 2014;42(5):844-52
55. Okada K, Shoda J, Kano M, et al. Inchinkoto, a herbal medicine, and its ingredients dually exert MRP2/MRP2-mediated choleresis and Nrf2-mediated antioxidative action in rat livers. Am J Physiol Gastrointest Liver Physiol 2007;292(5):G1450-63
56. Chai J, Luo D, Wu X, et al. Changes of organic anion transporter MRP4 and related nuclear receptors in human obstructive cholestasis. J Gastrointest Surg 2011;15(6):996-1004
57. Hrycay E, Forrest D, Liu L, et al. Hepatic bile acid metabolism and expression of cytochrome P450 and related enzymes are altered in Bsep (-/-) mice. Mol Cell Biochem 2014;389(1-2):119-32
58. Fukushima S, Okuno H, Shibatani N, et al. Effect of biliary obstruction and internal biliary drainage on hepatic cytochrome P450 isozymes in rats. World J Gastroenterol 2008;14(16):2556-60
59. Hasegawa Y, Kishimoto S, Takahashi H, et al. Altered expression of nuclear receptors affects the expression of metabolic enzymes and transporters in a rat model of cholestasis. Biol Pharm Bull 2009;32(12):2046-52
60. Choi YH, Lee YK, Lee MG. Effects of 17alpha-ethynylestradiol-induced cholestasis on the pharmacokinetics of doxorubicin in rats: reduced biliary excretion and hepatic metabolism of doxorubicin. Xenobiotica 2013;43(10):901-7
61. Zollner G, Wagner M, Fickert P, et al. Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis. Liver Int 2007;27(7):920-9
62. Chen HL, Liu YJ, Chen HL, et al. Expression of hepatocyte transporters and nuclear receptors in children with early and late-stage biliary atresia. Pediatr Res 2008;63(6):667-3
63. Chen J, Terada T, Ogasawara K, et al. Adaptive responses of renal organic anion transporter 3 (OAT3) during cholestasis. Am J Physiol Renal Physiol 2008;295(1):F247-52
64. Brandoni A, Villar SR, Picena JC, et al. Expression of rat renal cortical OAT1 and OAT3 in response to acute biliary obstruction. Hepatology 2006;43(5):1092-100
65. Marschall HU, Wagner M, Bodin K, et al. Fxr(-/-) mice adapt to biliary obstruction by enhanced phase I detoxification and renal elimination of bile acids. J Lipid Res 2006;47(3):582-92
66. Kurata T, Muraki Y, Mizutani H, et al. Elevated systemic elimination of cimetidine in rats with acute biliary obstruction: the role of renal organic cation transporter OCT2. Drug Metab Pharmacokinet 2010;25(4):328-34
67. Brandoni A, Anzai N, Kanai Y, et al. Renal elimination of p-aminohippurate (PAH) in response to three days of biliary obstruction in the rat. The role of OAT1 and OAT3. Biochim Biophys Acta 2006;1762(7):673-82
68. Brandoni A, Torres AM. Characterization of the mechanisms involved in the increased renal elimination of bromosulfophthalein during cholestasis: involvement of OATP1. J Histochem Cytochem 2009;57(5):449-56
69. Masuoka HC, Chalasani N. Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci 2013;1281:106-22
70. Lomonaco R, Sunny NE, Bril F, Cusi K. Nonalcoholic fatty liver disease: current issues and novel treatment approaches. Drugs 2013;73(1):1-14
71. Ali R, Cusi K. New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Ann Med 2009;41(4):265-78
72. Lake AD, Novak P, Fisher CD, et al. Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos 2011;39(10):1954-60
73. Hardwick RN, Fisher CD, Canet MJ, et al. Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease. Drug Metab Dispos 2011;39(12):2395-402
74. Fisher CD, Lickteig AJ, Augustine LM, et al. Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats. Eur J Pharmacol 2009;613(1-3):119-27
75. Lickteig AJ, Fisher CD, Augustine LM, et al. Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease. Drug Metab Dispos 2007;35(10):1970-8
76. Canet MJ, Hardwick RN, Lake AD, et al. Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models. Drug Metab Dispos 2014;42(4):586-95
77. Clarke JD, Hardwick RN, Lake AD, et al. Experimental nonalcoholic steatohepatitis increases exposure to simvastatin hydroxy acid by decreasing hepatic organic anion transporting polypeptide expression. J Pharmacol Exp Ther 2014;348(3):452-8
78. Barshop NJ, Capparelli EV, Sirlin CB, et al. Acetaminophen pharmacokinetics in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2011;52(2):198-202
79. Hardwick RN, Fisher CD, Street SM, et al. Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis. Drug Metab Dispos 2012;40(3):450-60
80. Clarke JD, Hardwick RN, Lake AD, et al. Synergistic interaction between genetics and disease on pravastatin disposition. J Hepatol 2014;61(1):139-47
81. Canet MJ, Hardwick RN, Lake AD, et al. Altered arsenic disposition in experimental nonalcoholic fatty liver disease. Drug Metab Dispos 2012;40(9):1817-24
82. Patoine D, Levac X, Pilote S, et al. Decreased CYP3A expression and activity in guinea pig models of diet-induced metabolic syndrome: is fatty liver infiltration involved? Drug Metab Dispos 2013;41(5):952-7
83. Fisher CD, Jackson JP, Lickteig AJ, et al. Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis. Arch Toxicol 2008;82(12):959-64
84. Vornoli A, Pozzo L, Della Croce CM, et al. Drug metabolism enzymes in a steatotic model of rat treated with a high fat diet and a low dose of streptozotocin. Food Chem Toxicol 2014;70C:54-60
85. Cui Y, Wang Q, Li X, Zhang X. Experimental nonalcoholic fatty liver disease in mice leads to cytochrome p450 2a5 upregulation through nuclear factor erythroid 2-like 2 translocation. Redox Biol 2013;1(1):433-40
86. Fisher CD, Lickteig AJ, Augustine LM, et al. Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos 2009;37(10):2087-94
87. Hardwick RN, Fisher CD, Canet MJ, et al. Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos 2010;38(12):2293-301
88. Aleksunes LM, Slitt AL, Maher JM, et al. Induction of MRP3 and MRP4 transporters during acetaminophen hepatotoxicity is dependent on Nrf2. Toxicol Appl Pharmacol 2008;226(1):74-83
89. Maher JM, Aleksunes LM, Dieter MZ, et al. Nrf2- and PPAR alpha-mediated regulation of hepatic MRP transporters after exposure to perfluorooctanoic acid and perfluorodecanoic acid. Toxicol Sci 2008;106(2):319-28
90. Cheng Q, Aleksunes LM, Manautou JE, et al. Drug-metabolizing enzyme and transporter expression in a mouse model of diabetes and obesity. Mol Pharm 2008;5(1):77-91
91. Phatchawan A, Chutima S, Varanuj C, Anusorn L. Decreased renal organic anion transporter 3 expression in type 1 diabetic rats. Am J Med Sci 2014;347(3):221-7